Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,801–1,900 of 4,275
Feng, J., Li, B., Wang, X., Li, H., Chen, Y., Xiao, W., Li, Z., Xie, L., Lu, W., Jiang, H., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.12.012 · Cited by 33
Chojak, R., Fares, J., Petrosyan, E., & Lesniak, M. S. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04387-3 · Cited by 35
Decreased autophagy and fuel switching occur in a senescent hepatic cell model system
Singh, B. K., Tripathi, M., Sandireddy, R., Tikno, K., Zhou, J., & Yen, P. M. (2020) · Aging · doi:10.18632/aging.103740 · Cited by 34
Cognitive Frailty is Associated With Elevated Proinflammatory Markers and a Higher Risk of Mortality
Diniz, B. S., Lima‐Costa, M. F., Peixoto, S. V., Firmo, J. O. A., Torres, K., Martins‐Filho, O. A., Teixeira‐Carvalho, A., Grady, J. J., Kuchel, G. A., & Costa, E. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.01.012 · Cited by 33
Senescence Alterations in Pulmonary Hypertension
Roger, I., Milara, J., Belhadj, N., & Cortijo, J. (2021) · Cells · doi:10.3390/cells10123456 · Cited by 40
Accumulation of Senescent Neural Cells in Murine Lupus With Depression-Like Behavior
Saito, Y., Miyajima, M., Yamamoto, S., Sato, T., Miura, N., Fujimiya, M., & Chikenji, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692321 · Cited by 32
“Collectively, these secreted factors are referred to as the SASP (48).”
BackgroundAli, I., Zhang, H., Zaidi, S. A. A., & Zhou, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102273 · Cited by 41
Mechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 36
“These phenotypic changes were dependent on the inflammatory cytokines IL-6 and IL-8 [30].”
BackgroundMitochondria pleiotropism in stem cell senescence: Mechanisms and therapeutic approaches
Mas‐Bargues, C. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.09.019 · Cited by 38
Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer
Alexander, P. B., Chen, R., Gong, C., Yuan, L., Jasper, J. S., Ding, Y., Markowitz, G. J., Yang, P., Xu, X., McDonnell, D. P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754960 · Cited by 35
“In addition to IGFBPs, senescent cells are known to produce and secrete a diverse assortment of proteins, including cytokines, chemokines, growth factors, adhesion molecules, and extracellular proteases (43, 44).”
BackgroundStress-induced (Premature) senescence
Debacq-Chainiaux, F., Ben Ameur, R., Bauwens, E., Dumortier, E., Toutfaire, M., & Toussaint, O. (2016) · Healthy Ageing and Longevity · doi:10.1007/978-3-319-26239-0_13 · Cited by 31
“An analysis of tumor tissues from patients treated with chemotherapeutic agents show a greater proportion of senescent cells (SA-ßgal positive, p16ink-4a overexpression) compared to healthy tissues in patients suffering from breast cancer, non-small-cell lung carcinoma or prostate cancer (Coppe et al. 2008; Roberson e…”
BackgroundHisamatsu, D., Ohno‐Oishi, M., Nakamura, S., Mabuchi, Y., & Naka-Kaneda, H. (2016) · Aging · doi:10.18632/aging.100982 · Cited by 34
Molecular basis of senescence transmitting in the population of human endometrial stromal cells
Griukova, A., Deryabin, P. I., Shatrova, A. N., Burova, E., Severino, V., Farina, A., Nikolsky, N. N., & Borodkina, A. V. (2019) · Aging · doi:10.18632/aging.102441 · Cited by 34
“Preserved synthetic activity along with malfunctioning of intracellular systems result in a gradual switch of the secretory profile of senescent cells, termed the senescence-associated secretory phenotype (SASP) [3].”
Netterfield, T. S., Ostheimer, G. J., Tentner, A. R., Joughin, B. A., Dakoyannis, A. M., Sharma, C. D., Sorger, P. K., Janes, K. A., Lauffenburger, D. A., & Yaffe, M. B. (2022) · Cell Systems · doi:10.1016/j.cels.2023.06.005 · Cited by 35
Maciel-Barón, L. Á., Morales-Rosales, S. L., Silva‐Palacios, A., Rodríguez‐Barrera, R., García, J. A., Luna‐López, A., Pérez, V., Torres, C. A., & Königsberg, M. (2018) · Biogerontology · doi:10.1007/s10522-018-9767-3 · Cited by 36
Herbert, B., Chanoux, R. A., Liu, Y., Baenziger, P. H., Goswami, C. P., McClintick, J. N., Edenberg, H. J., Pennington, R. E., Lipkin, S. M., & Kopelovich, L. (2010) · Oncotarget · doi:10.18632/oncotarget.175 · Cited by 33
“However, as the aging stroma has been shown to promote carcinogenesis [41, 45], the alterations in pathways involved with aging metabolism and inflammation observed in our study on one-hit TP53 cells may support other studies demonstrating the role of p53 in these processes [41, 46-47].”
ResultAlmasabi, S., Ahmed, A. U., Boyd, R. L., & Williams, B. R. G. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.638558 · Cited by 34
Epigenetic changes during ageing and their underlying mechanisms
Braga, D. L., Mousovich‐Neto, F., Tonon-da-Silva, G., Salgueiro, W. G., & Mori, M. A. (2020) · Biogerontology · doi:10.1007/s10522-020-09874-y · Cited by 35
Assessing Functional Roles of the Senescence-Associated Secretory Phenotype (SASP)
Malaquin, N., Tu, V., & Rodier, F. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8931-7_6 · Cited by 39
Self-citationEvaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling
Byrne, C. E., Decombe, J.-B., Bingham, G. C., Remont, J., Miller, L. G., Khalif, L., King, C. T., Hamel, K. M., Bunnell, B. A., Burow, M. E., et al. (2021) · Tissue Engineering Part A · doi:10.1089/ten.tea.2020.0364 · Cited by 33
“However, senescent cells can secrete molecules that promote tumorigenesis and transform cells in the microenvironment.(40,41) This is observed in cancer cells in metastatic sites, during evasion of immune response, and in cells that fail to respond to chemotherapy.”
BackgroundMesenchymal stromal cell senescence in haematological malignancies
Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10069-9 · Cited by 36
“1 with conditioned media collected from senescent fibroblasts induces epithelial-mesenchymal transition and enhanced invasiveness of cancer cells, thereby promoting a malignant cell phenotype [84].”
BackgroundRegulation of cGAS Activity and Downstream Signaling
Joshi, B., Joshi, J. C., & Mehta, D. (2022) · Cells · doi:10.3390/cells11182812 · Cited by 36
Phylogeny of aging and related phenoptotic phenomena
Libertini, G. (2015) · Biochemistry (Moscow) · doi:10.1134/s0006297915120019 · Cited by 31
MicroRNAs: a crossroad that connects obesity to immunity and aging
Rakib, A., Kiran, S., Mandal, M., & Singh, U. P. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00320-w · Cited by 37
“During obesity, adipocytes also function as endocrine cells and secrete adipokines, chemokines, and cytokines such as monocyte chemoattractant protein-1 (MCP-1) and TNF-α [31].”
BackgroundInfluentialLoss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC
Luo, C., Sheng, J., Hu, M. G., Haluska, F. G., Cui, R., Xu, Z., Tsichlis, P. N., Hu, G.-F., & Hinds, P. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4454 · Cited by 31
“Senescent cells secrete numerous factors including inflammatory cytokines, growth factors, and extracellular matrix remodeling enzymes that are collectively called the senescence-associated secretome (44).”
Dysregulation of the mTOR pathway in p53-deficient mice
Leontieva, O. V., Novototskaya, L. R., Paszkiewicz, G., Komarova, E. A., Gudkov, A. V., & Blagosklonny, M. V. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26947 · Cited by 33
“p53 may promote and suppress senescence.(23-31) While arresting cell cycle, p53 itself does not promote cellular senescence.”
BackgroundOdeh, A., Dronina, M. A., Domankevich, V., Shams, I., & Manov, I. (2019) · Aging Cell · doi:10.1111/acel.13045 · Cited by 32
“Its activation via phosphorylation of the p65 subunit and its nuclear translocation are necessary events for triggering secretion of pro‐inflammatory factors via this path‐ way, including IL6 and IL8.”
BackgroundInfluentialDissecting cellular senescence and SASP in Drosophila
Ito, T., & Igaki, T. (2016) · Inflammation and Regeneration · doi:10.1186/s41232-016-0031-4 · Cited by 36
Brief guide to senescence assays using cultured mammalian cells
Kang, E. S., Kang, C., Lee, Y., & Lee, S. (2024) · Molecules and Cells · doi:10.1016/j.mocell.2024.100102 · Cited by 41
Mixing old and young: enhancing rejuvenation and accelerating aging
Lau, A., Kennedy, B. K., Kirkland, J. L., & Tullius, S. G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123946 · Cited by 29
Hepatocyte senescence in vivo following preconditioning for liver repopulation
Serra, M. P., Marongiu, F., Sini, M., & Laconi, E. (2012) · Hepatology · doi:10.1002/hep.25698 · Cited by 31
Hino, Y., Nagaoka, K., Oki, S., Etoh, K., Hino, S., & Nakao, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac735 · Cited by 32
“Senescent cells have been found to cause mitochondrial dysfunction, either activation or decline, and a proinflammatory program referred to as the senescence-associated secretory phenotype (SASP) (64,65).”
Han, X., Zhang, T., Zhang, X., Zhang, R., Lao, K., Mi, Y., & Gou, X. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111347 · Cited by 35
Yang, J.-J., Zhao, S.-L., Zhang, X., Ma, Y., & Jiang, J. (2023) · Industrial Crops and Products · doi:10.1016/j.indcrop.2023.116903 · Cited by 30
Milewski, L. A. K. (2010) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzq001 · Cited by 33
“Unlike cells that undergo apoptosis, senescent cells seem refractory to immune clearance meaning they accumulate within tissue.(19) Exactly why such cells are not purged from tissue is unclear,(10) although one possibility is that these cells produce secretions that promote immune evasion.”
BackgroundInfluentialRegulation of cellular senescence by microRNAs
Ma, X., Zheng, Q., Zhao, G., Yuan, W., & Liu, W. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111264 · Cited by 30
Age-related dysfunction of the DNA damage response in intestinal stem cells
Watanabe, K., Ikuno, Y., Kakeya, Y., Ikeno, S., Taniura, H., Kurono, M., Minemori, K., Katsuyama, Y., & Naka-Kaneda, H. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0096-y · Cited by 31
Ullah, A., Chen, Y., Singla, R. K., Cao, D., & Shen, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107213 · Cited by 32
Aalaei‐Andabili, S. H., & Rezaei, N. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1077828 · Cited by 32
“Hence, IL-1α level in senescent cells is crucial factor in activation of significant level of IL-1R signaling system.”
BackgroundInfluentialTelomeres: beacons of autocrine and paracrine DNA damage during skin aging
Victorelli, S. G., & Passos, J. F. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1728016 · Cited by 36
“[1] Coppe JP, Patil CK, Rodier F, et al.”
BackgroundSoto-Gamez, A., Wang, Y., Zhou, X., Seras, L., Quax, W. J., & Demaria, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.038 · Cited by 42
Brain cellular senescence in mouse models of Alzheimer’s disease
Dorigatti, A. O., Riordan, R., Yu, Z., Ross, G., Wang, R., Reynolds-Lallement, N. C., Magnusson, K. R., Galván, V., & Pérez, V. (2022) · GeroScience · doi:10.1007/s11357-022-00531-5 · Cited by 35
“Senescent cells also activate a paracrine response which includes the coordinated expression of various proinflammatory cytokines, chemokines, and growth factors collectively known as the senescence-associated secretory phenotype (SASP) [8, 9] that is under control of mitogen-activated protein kinases and Nf-KB [10, 1…”
Aging promotes neoplastic disease through effects on the tissue microenvironment
Marongiu, F., Serra, M. P., Doratiotto, S., Sini, M., Fanti, M., Cadoni, E., Serra, M., & Laconi, E. (2016) · Aging · doi:10.18632/aging.101128 · Cited by 30
“Furthermore, levels of IL6, a pro-inflammatory cytokine and a major component of SASP which is also involved in liver regeneration and repair [16], were also higher in the liver of older animals.”
BackgroundMethodInfluentialBarros, P. R., Costa, T. J. D., Akamine, E. H., & Tostes, R. C. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.727604 · Cited by 34
Nano-Based Theranostic Tools for the Detection and Elimination of Senescent Cells
Adamczyk‐Grochala, J., & Lewińska, A. (2020) · Cells · doi:10.3390/cells9122659 · Cited by 32
“Abbreviations 17-AAG tanespimycin 17-DMAG alvespimycin AKT protein kinase B AMPK AMP-activated protein kinase B2M Beta-2 microglobulin Bcl-2 B cell lymphoma 2 family BETd BET family protein degrader CAR Chimeric antigen receptor CCL-16 Monotactin-1 CDKI Cyclin-dependent kinase inhibitor CS Cellular senescence DAMPs Da…”
BackgroundInfluentialPromises and challenges of senolytics in skin regeneration, pathology and ageing
Pils, V., Ring, N., Valdivieso, K., Lämmermann, I., Грубер, Ф., Schosserer, M., Grillari, J., & Ogrodnik, M. B. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111588 · Cited by 34
Enomoto, M., Vaughen, J. P., & Igaki, T. (2015) · Cancer Science · doi:10.1111/cas.12816 · Cited by 33
Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence
Chao, S. K., Horwitz, S. B., & McDaid, H. M. (2011) · Oncotarget · doi:10.18632/oncotarget.221 · Cited by 33
“Recent studies, including our own, demonstrate that senescence can occur in cells that have compromised p53 [15, 43, 63-65].”
BackgroundSieben, C. J., Jeganathan, K. B., Nelson, G. G., Sturmlechner, I., Zhang, C., van Deursen, W. H., Bakker, B., Foijer, F., Li, H., Baker, D. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126863 · Cited by 30
“These findings suggest that there is substantially more heterogeneity in bioactive secretomes in vivo than expected based on initial in vitro data (41).”
BackgroundExploring mechanisms of skin aging: insights for clinical treatment
Zhang, M., Lin, Y., Han, Z., Huang, X., Zhou, S., Wang, S., Zhou, Y., Han, X., & Chen, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1421858 · Cited by 49
A nutrigeroscience approach: Dietary macronutrients and cellular senescence
Calubag, M. F., Robbins, P. D., & Lamming, D. W. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.025 · Cited by 35
Zhao, X., Li, J., Liu, Z., & Powers, S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2555 · Cited by 31
Zhang, N., Ji, J., Zhou, D., Liu, X., Zhang, X., Liu, Y., Xiang, W., Wang, M., Zhang, L., Wang, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020849 · Cited by 33
“have shown that SASP contributes to tumor progression by promoting EMT in neighboring immortalized or transformed epithelial cells [16,17].”
BackgroundInfluentialWątroba, M., Maślińska, D., & Maśliński, S. (2012) · Advances in Medical Sciences · doi:10.2478/v10039-012-0039-1 · Cited by 34
Kapralova, K., Jahoda, O., Kořalková, P., Gurský, J., Lanikova, L., Pospíšilová, D., Divoký, V., & Horváthová, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249652 · Cited by 34
“To assess the involvement of cell-intrinsic production of cytokines and other secreted factors in the pathologies observed in Rpl5- and Rps19-deficient cells, we tested if a conditioned medium from mutant cells can induce cell-nonautonomous responses (bystander effects) in control cells [31].”
BackgroundTargeting senescent cells for the treatment of age-associated diseases
Suda, M., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae091 · Cited by 39
Zillmer, R., Trøstrup, H., Karlsmark, T., Ifversen, P., & Ågren, M. S. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1164-6 · Cited by 33
Sensitive Detection and Monitoring of Senescence-Associated Secretory Phenotype by SASP-RAP Assay
Gu, L., & Kitamura, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052305 · Cited by 32
Chamoli, M., Chinta, S. J., & Andersen, J. K. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1887-z · Cited by 31
TGF‑β induces periodontal ligament stem cell senescence through increase of ROS production
Fan, C., Ji, Q., Zhang, C., Xu, S., Sun, H., & Li, Z. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10580 · Cited by 46
“The acquisition of a senescence-associated secretory phenotype (SaSP) reinforces senescence and stimulates the immune system to clear the senescent cells (15). cellular senescence can be induced by various stimuli and stressors, including dna damage, metabolic insults, oxidative stresses, oncogene activation and epige…”
BackgroundInfluentialThe significance of the senescence pathway in breast cancer progression
Pare, R. B., Yang, T., Shin, J., & Lee, C. S. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201081 · Cited by 34
Arnold, R., Vehns, E., Randl, H., & Djabali, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147474 · Cited by 35
“Together, these factors are termed SASPs [76].”
InfluentialApoptosis signal-regulating kinase 1 promotes inflammation in senescence and aging
Odawara, T., Yamauchi, S., & Ichijo, H. (2024) · Communications Biology · doi:10.1038/s42003-024-06386-0 · Cited by 30
“In addition, our results suggest that ASK1 is dispensable for p16 and p21 expression during OIS and DIS.”
InfluentialMicroRNA and Senescence: The Senectome, Integration and Distributed Control
Bilsland, A. E., Revie, J., & Keith, W. N. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2013007197 · Cited by 29
cGAS‐STING signaling in cancer: Regulation and therapeutic targeting
Fan, X., Song, X., Chen, W., Liang, H., Nakatsukasa, H., & Zhang, D. (2023) · MedComm – Oncology · doi:10.1002/mog2.49 · Cited by 30
Kuehnemann, C., Hughes, J. B., Desprez, P., Melov, S., Wiley, C. D., & Campisi, J. (2022) · Aging Cell · doi:10.1111/acel.13750 · Cited by 28
Self-citationP21 Overexpression Promotes Cell Death and Induces Senescence in Human Glioblastoma
Mansour, M. A., Rahman, M., Ayad, A. A., Warrington, A. E., & Burns, T. C. (2023) · Cancers · doi:10.3390/cancers15041279 · Cited by 33
p16INK4a Expression and Breast Cancer Risk in Women with Atypical Hyperplasia
Radisky, D. C., Santisteban, M., Berman, H. K., Gauthier, M. L., Frost, M. H., Reynolds, C. A., Vierkant, R. A., Pankratz, V. S., Visscher, D. W., Tlsty, T. D., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0282 · Cited by 28
“potentially to serve a tumor suppressive function; however, cells in which p16 expression is maintained for extended periods of time are known to secrete proteins that alter tissue structure and function and promote tumor development (30, 31).”
p53 mutation and deletion contribute to tumor immune evasion
Liu, S. M., Liu, T., Jiang, J., Guo, H., & Yang, R. L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1088455 · Cited by 41
“IL-6, and IL-8 caused the loss of p53 in normal cells and the p53 deficiency exacerbated the pro-malignant secretory activity, forming a vicious cycle (Downward et al., 2008).”
BackgroundOchratoxin A induced premature senescence in human renal proximal tubular cells
Yang, X., Liu, S., Huang, C. S., Wang, H., Luo, Y., Xu, W., & Huang, K. (2017) · Toxicology · doi:10.1016/j.tox.2017.03.009 · Cited by 30
Zheng, T., Que, Z., Jiao, L., Kang, Y., Gong, Y., Yao, J., Ma, C., Bi, L., Dong, Q., Zhao, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05146-x · Cited by 30
Misexpression of genes lacking CpG islands drives degenerative changes during aging
Lee, J.-Y., Davis, I., Youth, E. H. H., Kim, J., Churchill, G. A., Godwin, J. W., Korstanje, R., & Beck, S. (2021) · Science Advances · doi:10.1126/sciadv.abj9111 · Cited by 27
Coppola, D., Balducci, L., Chen, D., Loboda, A. P., Nebozhyn, M., Staller, A., Fulp, W. J., Dalton, W. S., Yeatman, T. J., & Brem, S. S. (2014) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2014.08.003 · Cited by 34
Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development
Hara, E. (2015) · Digestive Diseases · doi:10.1159/000371679 · Cited by 33
Li, B., Zhang, G. C., Wang, Z., Yang, Y., Wang, C., Fang, D., Liu, K., Wang, F., & Mei, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04330-2 · Cited by 30
Oxidative stress in the etiology of age-associated decline in glucose metabolism
Salmon, A. B. (2012) · Longevity & Healthspan · doi:10.1186/2046-2395-1-7 · Cited by 32
“Oxidative stress also promotes cellular senescence, particularly in adipocytes; these senescent cells can then promote localized inflammation by secreting proinflammatory cytokines and by recruiting macrophages [86-88].”
BackgroundHellicar, J., Stevenson, N. L., Stephens, D. J., & Lowe, M. (2022) · Journal of Cell Science · doi:10.1242/jcs.258879 · Cited by 32
Buonfiglio, F., Korb, C. A., Stoffelns, B. M., Pfeiffer, N., & Gericke, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.0124 · Cited by 54
“A reduced rate of functional mitophagy can result in reduced clearance of damaged mitochondria, leading to the release of mtDNA fragments and ROS, possibly culminating in AMD pathogenesis [222-224].”
An evolutionary transcriptomics approach links CD36 to membrane remodeling in replicative senescence
Saitou, M., Lizardo, D. Y., Taşkent, R. Ö., Millner, A., Gökçümen, Ö., & Atilla‐Gokcumen, G. E. (2018) · Molecular Omics · doi:10.1039/c8mo00099a · Cited by 43
Senoptosis: non-lethal DNA cleavage as a route to deep senescence
Studencka, M., & Schaber, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15693 · Cited by 29
“Furthermore, knowing that seven days after irradiation about 50% of cells belong to the sub-G1 population (Figure 1D), the lack of the SASP in the sub-G1 Oncotarget30662www.impactjournals.com/oncotarget population (Figure 3B) implies that only a minority of irradiated cells actually exhibit the senescence-associated s…”
BackgroundInfluentialLi, J., Karim, M. A., Che, H., Geng, Q., & Miao, D. (2020) · PubMed · doi:10.6094/unifr/166811 · Cited by 36
Sowing the seeds of cancer: telomeres and age-associated tumorigenesis
Pereira, B. I., & Ferreira, M. G. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6358 · Cited by 33
“These results confirm that sustained DDR signalling is fundamental for the activation of the senescence programme and cytokine secretion that constitutes the SASP.”
BackgroundInfluentialThe Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer
Mori, J., Elhussin, I. A., Brennen, W. N., Graham, M. K., Lotan, T. L., Yates, C. C., Marzo, A. M. D., Denmeade, S. R., Yegnasubramanian, S., Nelson, W. G., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00827-x · Cited by 35
“However, SASP factors stimulate the proliferation and survival of nearby cells, including cancer cells 9,17,19 .”
InfluentialGhosh, A., Michels, J., Mezzadra, R., Venkatesh, D., Dong, L., Gomez, R., Samaan, F., Ho, Y.-J., Campesato, L. F., Mangarin, L. M. B., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148141 · Cited by 34
“This is not surprising, as p53 itself can transcriptionally repress some of the SASP genes that are associated with genotoxic agents, and therefore some of the detrimental effects of conventional SASP such as chronic inflammation are subdued (32, 35).”
BackgroundLow-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro
Lévêque, X., Hochane, M., Geraldo, F., Dumont, S., Gratas, C., Oliver, L., Gaignier, C., Trichet, V., Layrolle, P., Heymann, D., et al. (2019) · Stem Cells · doi:10.1002/stem.3014 · Cited by 32
Developing transcriptomic signatures as a biomarker of cellular senescence
Mahmud, S., Pitcher, L. E., Torbenson, E., Robbins, P. D., Zhang, L., & Dong, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102403 · Cited by 39
Cell Senescence and Central Regulators of Immune Response
Lunin, S. M., Novoselova, E. G., Glushkova, O. V., Parfenyuk, S. B., Novoselova, T. V., & Khrenov, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084109 · Cited by 31
Valenzuela, C. A., Quintanilla, R., Olate‐Briones, A., Venturini, W., Mancilla, D., Cayo, Á., Moore‐Carrasco, R., & Brown, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215292 · Cited by 30
“Accordingly, factors secreted by senescent fibroblasts can promote proliferation and migration of premalignant epithelial cells [26,28,31,32].”
BackgroundA Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal
Mastri, M., Tracz, A., Lee, C. R., Dolan, M., Attwood, K., Christensen, J. G., Liu, S., & Ebos, J. M. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.017 · Cited by 28
“…tumor growth via senescence-associated secretory phenotypes (SASPs) that include cytokines and growth factors capable of activating auto/paracrine tumor/stromal interactions that facilitate metastatic spread (Ewald et al., 2010; Tchkonia et al., 2013; Coppé et al., 2008, 2010; Lecot et al., 2016).”
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
Martino, S. D., Amoreo, C. A., Nuvoli, B., Galati, R., Strano, S., Facciolo, F., Alessandrini, G., Pass, H. I., Ciliberto, G., Blandino, G., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0044-8 · Cited by 29
Antagonistic TSC22D1 variants control BRAFE600‐induced senescence
Cornelia, H.-H., van Doorn, R., Vogel, C., Germann, M., Cecchini, M. G., Verdegaal, E. M. E., & Peeper, D. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.95 · Cited by 31
“Some of those depend on a persistent DDR, and this phenomenon has been termed senescence- associated secretory phenotype (SASP) (Coppe et al, 2008; Rodier et al, 2009).”
BackgroundPrime, S. S., Cirillo, N., Cheong, S. C., Prime, M. S., & Parkinson, E. K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.025 · Cited by 31
Kawamura, Y., Oka, K., Semba, T., Takamori, M., Sugiura, Y., Yamasaki, R., Suzuki, Y., Chujo, T., Nagase, M., Oiwa, Y., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022111133 · Cited by 33
Cross-senolytic effects of dasatinib and quercetin in humans
Tqemaladze, J. (2023) · GEORGIAN SCIENTISTS · doi:10.52340/2023.05.03.15 · Cited by 69
Chemerinski, A., de Paredes, J. G., Blackledge, K. T., Douglas, N. C., & Morelli, S. S. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1332946 · Cited by 32
Cellular senescence is a key mediator of lung aging and susceptibility to infection
Torrance, B. L., & Haynes, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006710 · Cited by 32
“Interestingly, IL-6 is also among the most consistent factors present in the SASP of senescent cells (18).”
BackgroundDistinct secretomes in p16- and p21- positive senescent cells across tissues
Saul, D., Jurk, D., Doolittle, M. L., Kosinsky, R. L., Monroe, D. G., LeBrasseur, N. K., Robbins, P. D., Niedernhofer, L. J., Khosla, S., & Passos, J. F. (2023) · doi:10.1101/2023.12.05.569858 · Cited by 28
Higashiguchi, M., Murakami, H., Hirofumi, H., Kobayashi, S., Takahama, S., Iwagami, Y., Yamada, D., Tomimaru, Y., Noda, T., Gotoh, K., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8535 · Cited by 30
Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside
Brawerman, G. M., & Thompson, P. J. (2020) · Biomolecules · doi:10.3390/biom10121681 · Cited by 30
“However, in the context of T1D, SASP seems to go unresolved as senescent beta cells continue to accumulate during disease progression [69].”
BackgroundInfluential
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.